Xilio Therapeutics (NASDAQ:XLO) is a pioneering biotechnology company dedicated to revolutionizing cancer treatment through its innovative immuno-oncology platform. Leveraging cutting-edge science, Xilio develops next-generation tumor-targeted immuno-therapies aimed at enhancing the body's natural immune response to fight cancer. With a focus on precision medicine, their proprietary technology enables precise delivery of therapeutic agents directly to tumor sites, minimizing systemic toxicity and maximizing efficacy. Xilio's robust pipeline includes novel candidates designed to address a wide range of cancers, offering hope for patients with unmet medical needs. Committed to transforming cancer care, Xilio Therapeutics is at the forefront of advancing the future of oncology.